Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer
NCT04729608
Terminated
This is a randomized, double-blind Phase 3 study to compare the efficacy and safety of batiraxcept (AVB-S6-500) in combination with paclitaxel (PAC) versus placebo in combination with PAC in patients with platinum resistant recurrent ovarian cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/26/2023
Locations: University of Pennsylvania Health System, Philadelphia, Pennsylvania +4 locations
Conditions: Platinum-resistant Ovarian Cancer
Register for Updates
PBI-MST-01(NCT04541108) Substudy TAK-02: Intratumoral Microdosing of TAK-676 in HNSCC
NCT06062602
Completed
This is a multi-center, open-label Phase 0 substudy designed to study the localized pharmacodynamics (PD) of TAK-676 alone or in combination with Carboplatin, 5-FU, or Paclitaxel within the tumor microenvironment (TME) when administered intratumorally in microdose quantities via the CIVO device in patients diagnosed with Head and Neck Squamous Cell Carcinoma presenting with a surface accessible solid tumor for which there is a scheduled surgical intervention. This substudy is a cohort of the PBI... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/03/2023
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Head and Neck Squamous Cell Carcinoma
Register for Updates
MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.
NCT03611556
Completed
The objective of this study is to evaluate the safety, tolerability, and antitumor activity of oleclumab (MEDI9447) in combination with or without durvalumab plus chemotherapy in participants with metastatic pancreatic cancer.
Gender:
ALL
Ages:
Between 18 years and 101 years
Trial Updated:
09/08/2023
Locations: Research Site, Philadelphia, Pennsylvania
Conditions: Carcinoma, Metastatic Pancreatic Adenocarcinoma
Register for Updates
AO-176 in Multiple Solid Tumor Malignancies
NCT03834948
Completed
This is a first-in-human, Phase 1/2 multi-center, open-label, dose escalation and expansion study of AO-176 which will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and clinical effects of AO-176 in patients with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/21/2023
Locations: Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania
Conditions: Solid Tumor
Register for Updates
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
NCT01196390
Completed
This randomized phase III trial studies how well radiation therapy, paclitaxel, and carboplatin with or without trastuzumab work in treating patients with esophageal cancer. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as trastuzumab,... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/16/2023
Locations: UPMC-Heritage Valley Health System Beaver, Beaver, Pennsylvania +31 locations
Conditions: Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Stage IB Esophageal Cancer AJCC v7, Stage IIA Esophageal Cancer AJCC v7, Stage IIB Esophageal Cancer AJCC v7, Stage IIIA Esophageal Cancer AJCC v7, Stage IIIB Esophageal Cancer AJCC v7
Register for Updates
Genetic Predictors of Benefit to Pembrolizumab
NCT02710396
Terminated
The primary objective is to determine if mutation load underlies sensitivity to pembrolizumab alone and in combination with chemotherapy. This will be a 3-arm, multi-center, open-label, non-randomized biomarker trial in patients with advanced, treatment-naive NSCLC. Patients will receive 1 of 3 possible cohorts as per investigator's discretion. Patients with non-squamous histology may receive any of the 3 cohorts; patients with squamous histology may receive either cohorts 1 and 2.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/21/2023
Locations: Fox Chase Cancer Center, Philadelphia, Pennsylvania
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors
NCT03184870
Completed
The purpose of this study is to evaluate the safety profile, tolerability, drug levels, drug effects, and preliminary efficacy of BMS-813160 alone or in combination with either chemotherapy or nivolumab or chemotherapy plus nivolumab in participants with metastatic colorectal and pancreatic cancers.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/30/2023
Locations: Local Institution - 0037, Allentown, Pennsylvania +2 locations
Conditions: Colorectal Cancer, Pancreatic Cancer
Register for Updates
Paclitaxel Plus Gemcitabine in Treating Patients With Refractory Metastatic Germ Cell Tumors
NCT00003518
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of paclitaxel plus gemcitabine in treating patients with refractory metastatic germ cell tumors that have not responded to surgery or chemotherapy.
Gender:
ALL
Ages:
Between 15 years and 120 years
Trial Updated:
06/21/2023
Locations: Hahnemann University Hospital, Philadelphia, Pennsylvania
Conditions: Ovarian Cancer, Testicular Germ Cell Tumor
Register for Updates
Methotrexate Compared With Paclitaxel in Treating Patients With Advanced Head and Neck Cancer
NCT00003592
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether methotrexate or paclitaxel is more effective in treating patients with advanced head and neck cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of methotrexate with that of paclitaxel in treating patients who have advanced head and neck cancer that cannot be treated with cisplatin.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
06/21/2023
Locations: Fox Chase Cancer Center, Philadelphia, Pennsylvania
Conditions: Head and Neck Cancer
Register for Updates
Cisplatin and Fluorouracil Compared With Carboplatin and Paclitaxel in Treating Patients With Inoperable Locally Recurrent or Metastatic Anal Cancer
NCT02560298
Active Not Recruiting
This randomized phase II trial studies how well cisplatin and fluorouracil work compared with carboplatin and paclitaxel in treating patients with anal cancer that cannot be removed by surgery, has come back at or near the same place as the primary tumor, or spread to other places in the body. Drugs used in chemotherapy, such as cisplatin, fluorouracil, carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividin... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/21/2023
Locations: ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania
Conditions: Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma, Anal Squamous Cell Carcinoma, Metastatic Anal Canal Carcinoma, Recurrent Anal Canal Carcinoma, Stage IIIB Anal Canal Cancer, Stage IV Anal Canal Cancer
Register for Updates
Combination Chemotherapy After Surgery in Treating Patients With Cancer of the Esophagus or Stomach
NCT00003237
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug, and giving them after surgery, may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy, consisting of paclitaxel and cisplatin, given after surgery in treating patients with cancer of the esophagus or stomach.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
06/21/2023
Locations: Allegheny University Hospitals- Hahnemann, Philadelphia, Pennsylvania +4 locations
Conditions: Esophageal Cancer, Gastric Cancer
Register for Updates
Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Gastric Cancer
NCT00003298
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy, radiation therapy, and surgery may kill more tumor cells. E7296 was conducted to study neoadjuvant chemotherapy and postoperative chemoradiation therapy in patients diagnosed with high-risk gastric cancer using a new neoadjuvant regimen: paclitaxel plus cisplatin. It was hypothesized that t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/21/2023
Locations: University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania +1 locations
Conditions: Gastric Cancer
Register for Updates